The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
Dr. Alex Reimann is a leading naturopathic physician. She has devoted her life to cancer patients and others in need.
If you have been mailed a fundraising packet and still have donor cards to send out, it is not too late. Consider passing one on to a neighbor co-worker, friend or family member.
“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.
How does a $2 million-a-year cancer research effort with a team of nine scientists keep pace with a $100 million-a-year project with a team of 200? Pretty well, it turns out. With the Cancer Genome Atlas project in the news lately—the New York Times recently reported on progress in its colon cancer work—we decided to compare some of its data with that of the Life Raft Group’s Research Team and its D-Day Project. Our research focuses on GIST.
The first in a series of New York Times articles by science writer Gina Kolata on new approaches to cancer treatment underscored the type of cutting-edge approaches taken by the Life Raft Group’s own team of researchers. [...]
The Life Raft Group will be marking a milestone at Life Fest 2012: Celebrating 10 Years of Dedication on November 9 to 11 at the Red Rock Casino in Las Vegas. We are at a [...]
Brenda Bannon of Berne, New York, calls her 10-year cancer-versary more of a marker or a stepping stone than a celebration. A stepping stone to a cure.
Often, in the LRG email community, members have been known to offer suggestions on everything from what to bring with you to the hospital to managing side-effects. Louise Ladd is one of those people and [...]
KIT functions in several distinct cell types. Keep reading to learn about KIT signaling and new approaches for GIST Therapy.
